GT
NKTR icon

Glenmede Trust’s Nektar Therapeutics NKTR Stock Holding History

Glenmede Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Sell
13,460
-405
-3% -$29.6K ﹤0.01% 794
2026
Q1 		$998K Buy
13,865
+5,275
+61% +$300K ﹤0.01% 740
2025
Q4 		$363K Buy
+8,590
New +$481K ﹤0.01% 1060
2020
Q4 		– Sell
-94
Closed -$23K – 1872
2020
Q3 		$23K Sell
94
-4
-4% -$1.26K ﹤0.01% 1575
2020
Q2 		$34K Sell
98
-78
-44% -$24.3K ﹤0.01% 1415
2020
Q1 		$56K Hold
176
– – ﹤0.01% 1640
2019
Q4 		$56K Hold
176
– – ﹤0.01% 1640
2019
Q3 		$47K Hold
176
– – ﹤0.01% 1683
2019
Q2 		$93K Hold
176
– – ﹤0.01% 1433
2019
Q1 		$88K Hold
176
– – ﹤0.01% 1453
2018
Q4 		$86K Buy
+176
New +$106K ﹤0.01% 1407
2018
Q3 		– Sell
-33
Closed -$24K – 1686
2018
Q2 		$24K Buy
33
+3
+10% +$3.46K ﹤0.01% 1664
2018
Q1 		$26K Hold
30
– – ﹤0.01% 1859
2017
Q4 		$26K Buy
+30
New +$17.7K ﹤0.01% 1859
2016
Q4 		– Sell
-4
Closed -$1K – 2562
2016
Q3 		$1K Buy
+4
New +$1.03K ﹤0.01% 2487
2015
Q4 		– Sell
-145
Closed -$23K – 2728
2015
Q3 		$23K Hold
145
– – ﹤0.01% 1855
2015
Q2 		$27K Hold
145
– – ﹤0.01% 1810
2015
Q1 		$23K Hold
145
– – ﹤0.01% 1902
2014
Q4 		$33K Buy
+145
New +$31K ﹤0.01% 1876

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's NKTR Position: Q2 2026 in Review

Glenmede Trust reduced its Nektar Therapeutics (NKTR) stake by 2.9% in Q2 2026, selling an estimated $29.6K and leaving 13,460 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Glenmede Trust first reported a position in NKTR in Q4 2014 and has held it in 19 quarters since. The position peaked at $998K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Glenmede Trust held 13,460 shares of Nektar Therapeutics worth $940K as of Q2 2026.
  • Glenmede Trust sold 405 Nektar Therapeutics shares in Q2 2026, an estimated $29.6K.
  • Nektar Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #794 holding.
  • Glenmede Trust first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 19 quarters since.
  • Glenmede Trust's Nektar Therapeutics position peaked at $998K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.